Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, Lecce, Italy.
Methods Mol Biol. 2021;2213:49-58. doi: 10.1007/978-1-0716-0954-5_5.
New biologically active compounds are regularly discovered through screening procedures using microorganisms. This very cheap procedure is followed by drug discovery that is usually seen as a highly focused approach, testing new compounds on animals or cell lines. In vivo assays of candidate drugs in mammals are expensive and sometimes not affordable at the preliminary stages of drug development. Early screening approaches in transgenic plants would allow chemotherapeutic drug candidates further selection before their characterization in expensive biological models. The proposed screening approach is based on cell subcellular architecture observations in transgenic plants within a short time of treatment, which is better than observing the effects of compounds on growth.
新的生物活性化合物通常通过使用微生物进行筛选程序来发现。这一非常廉价的程序之后是药物发现，通常被视为一种高度集中的方法，即在动物或细胞系上测试新化合物。在哺乳动物体内对候选药物进行测试既昂贵，在药物开发的初步阶段有时又无法负担。在昂贵的生物模型中对候选化疗药物进行特征描述之前，在转基因植物中进行早期筛选方法将允许进一步选择。所提出的筛选方法基于转基因植物中细胞亚细胞结构在短时间治疗后的观察，这比观察化合物对生长的影响要好。
